NOVEL TREATMENT STRATEGIES FOR ALK+ NSCLC: FROM EVIDENCE TO PRACTICE

MESSE WIEN EXHIBITION & CONGRESS CENTER
LEHAR 3 + 4
TUESDAY 6 DECEMBER 2016
12:45–14:15
VIENNA, AUSTRIA

This presentation was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.

This scientific meeting may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This programme and/or material was developed for use outside of the USA, is intended for non-US HCPs, and is to be used in accordance with local laws and regulations.

SUPPORTED BY

NOVARTIS
Dear Colleague,

You are cordially invited to participate in the Novartis satellite symposium Novel treatment strategies for ALK+ NSCLC: from evidence to practice, which will be held on Tuesday 6 December 2016 during the 17th World Conference on Lung Cancer in Vienna, Austria.

A panel of internationally recognized experts in the field of lung cancer will share their insights and experiences in treating patients with ALK+ NSCLC. Engaging and interactive case-study presentations will exemplify how to optimize and individualize treatment for your patients with ALK+ NSCLC. The symposium will culminate in an engaging and lively discussion about the challenges you may face when deciding on a treatment sequence for ALK+ NSCLC patients.

Your perspectives and contributions are very valuable to us, and we invite you to engage with us and join the discussion. We look forward to seeing you, and to hearing your views, at what will be a stimulating and highly informative event.

Solange Peters
Chair

OBJECTIVES

- Highlight the clinical characteristics that differentiate ALK+ NSCLC patients from the overall NSCLC population
- Share experiences from clinical practice in optimizing treatment for patients with ALK+ NSCLC
- Provide an outlook on the future of the ALK+ NSCLC treatment landscape
- Discuss optimal treatment sequences for patients with ALK+ NSCLC

PROGRAMME

12:45–12:50  WELCOME AND INTRODUCTION
SOLANGE PETERS (SWITZERLAND)

12:50–13:05  ALK+ NSCLC: NOT YOUR TYPICAL PATIENTS
HEATHER WAKELEE (USA)

13:05–13:20  OPTIMIZING OUTCOMES FOR YOUR ALK+ NSCLC PATIENTS
FABRICE BARLESI (FRANCE)

13:20–13:40  THE FUTURE OF ALK+ NSCLC TREATMENT AND WHAT THIS IMPLIES FOR YOUR CLINICAL PRACTICE
DANIEL TAN (SINGAPORE)

13:40–14:10  PANEL DISCUSSION: CHALLENGES IN SEQUENCING THERAPY FOR YOUR ALK+ NSCLC PATIENTS
ALL FACULTY

14:10–14:15  CONCLUSIONS AND CLOSE
SOLANGE PETERS (SWITZERLAND)